Mitomycin is used off-label in an aqueous solution, which has a relatively short dwell time in the bladder of only about 5 minutes, ie it is gone with the first voiding. Mitomycin also causes ...

Data from the phase 3 ENVISION trial demonstrate the potential of UGN-102 as an effective and durable nonsurgical treatment for patients with low-grade, intermediate-risk non–muscle-invasive bladder ...

BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with ...

Epirubicin propylaxis after TUR appeared to be as effective as mitomycin in patients with primary tumours. Recurrence rates and recurrence-free intervals were similar with the 2 agents. [5] ...

Bladder cancer is a cancer that forms in tissues of the bladder. Most bladder cancers are transitional cell carcinomas (cancer that begins in cells that normally make up the inner lining of the ...